Holen Sie sich die Stockscreener-App
29.06
0.08%
-0.14
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$29.20
Offen:
$29.28
24-Stunden-Volumen:
83,149
Relative Volume:
0.04
Marktkapitalisierung:
$4.85B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
14.90
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
-6.00%
1M Leistung:
-14.51%
6M Leistung:
+0.89%
1J Leistung:
-17.58%
1-Tages-Spanne:
$28.94
$29.28
1-Wochen-Bereich:
$28.91
$31.44
52-Wochen-Spanne:
$25.16
$36.32
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
29.12 | 4.87B | 1.51B | 333.35M | 315.22M | 1.95 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.10 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.16 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.52 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.51 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.45 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-11 | Eingeleitet | Truist | Buy |
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Celebrating LGBTQIA+ Mental Health Trailblazers - CSRwire
Alkermes Reports 2025 Financials, Advances Narcolepsy Pipeline, Announces CEO Succession - Sleep Review
Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen - Yahoo Finance
Alkermes (NASDAQ: ALKS) insider sells common stock via Form 144 - Stock Titan
Alkermes (ALKS) Rule 144: Insider sale notice for 6,000 shares, $180K - Stock Titan
5,000-share exercise and multiple sales reported by Alkermes (ALKS) - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: Exploring A 45% Potential Upside In Biopharma - DirectorsTalk Interviews
Alkermes Releases Third Annual Corporate Responsibility Report - CSRwire
ALKSAlkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013 - ADVFN Ltd
Alkermes (ALKS) VP exercises RSUs and withholds 808 shares for tax - Stock Titan
Alkermes (ALKS) CCO logs RSU exercise and tax share withholding - Stock Titan
Alkermes (ALKS) COO logs RSU share gain and tax-related share disposal - Stock Titan
Alkermes (ALKS) EVP Hopkinson converts 6,866 RSUs, withholds 3,049 shares for taxes - Stock Titan
Alkermes (ALKS) EVP Gaffin exercises RSUs, withholds 3,049 shares for tax - Stock Titan
Alkermes’ ALKS 2680 Narcolepsy Study Completion: What Investors Should Watch Next - TipRanks
Alkermes plc $ALKS Shares Sold by Primecap Management Co. CA - MarketBeat
H.C. Wainwright lowers Alkermes stock price target on revenue guidance By Investing.com - Investing.com Canada
4 Analysts Have This To Say About Alkermes - Benzinga
Wells Fargo Boosts Price Target for Alkermes (ALKS), Maintains O - GuruFocus
ALKS: RBC Capital Adjusts Price Target; Maintains Outperform Rat - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Alkermes (NASDAQ:ALKS) Stock Price - MarketBeat
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change - Zacks Investment Research
Alkermes Reveals CEO Succession Plan Following Richard Pops’ Retirement Announcement - Pharmaceutical Executive
RBC Lowers Price Target on Alkermes to $45 From $47, Keeps Outperform Rating - marketscreener.com
Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript - Insider Monkey
Alkermes Plc earnings missed by $0.12, revenue topped estimates - Investing.com Australia
Decoding Alkermes PLC (ALKS): A Strategic SWOT Insight - GuruFocus
Alkermes CEO Richard Pops to retire after 35 years, Jackson named successor - Investing.com Nigeria
Alkermes plc 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ALKS) 2026-02-25 - Seeking Alpha
Alkermes FY 2025 presentation: transition year sets stage for growth By Investing.com - Investing.com Australia
Alkermes Earnings Call: Growth, LUMRIZE and New Risks - TipRanks
Does Alkermes’ Weaker 2025 Results and CEO Changeover Shift the Bull Case for ALKS? - Yahoo Finance
Alkermes (NASDAQ: ALKS) COO exercises RSUs, shares withheld for tax - Stock Titan
S&E In Brief: Commercial Updates From The SMID Cap Universe - Citeline News & Insights
Alkermes (ALKS) Announces CEO Transition as Shares Dip - GuruFocus
Alkermes (ALKS) Q4 2025 Earnings Call Transcript - The Globe and Mail
Is Alkermes (ALKS) Pricing In Its Neuroscience And Orexin Pipeline Potential? - simplywall.st
Alkermes Announces CEO Succession and Leadership Transition Plan - TipRanks
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 - 富途牛牛
Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Alkermes Q4 Earnings Call Highlights - MarketBeat
Alkermes Q4 2025 Earnings Call Transcript - MarketBeat
Alkermes’ Richard Pops to step down after three-decade run as CEO - BioPharma Dive
Alkermes (ALKS) Reports Strong Q4 Revenue, Sets Ambitious 2026 G - GuruFocus
Alkermes plc Q4 2025 Earnings Call Summary - Yahoo Finance
Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Alkermes (NASDAQ:ALKS) Shares Down 6.7% on Disappointing Earnings - MarketBeat
Alkermes (NASDAQ:ALKS) Issues Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Alkermes FY 2025 presentation: transition year sets stage for growth - Investing.com
Alkermes shares rise after revenue beat and upbeat outlook offsets earnings miss - MSN
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.71%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):